Humana Inc. (NYSE:HUM) Shares Sold by Mascoma Wealth Management LLC

Mascoma Wealth Management LLC decreased its position in Humana Inc. (NYSE:HUM) by 14.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 242 shares of the insurance provider’s stock after selling 42 shares during the period. Mascoma Wealth Management LLC’s holdings in Humana were worth $61,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Transcend Capital Advisors LLC grew its position in Humana by 399.7% in the fourth quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock worth $924,000 after acquiring an additional 2,914 shares during the period. FNY Investment Advisers LLC lifted its stake in shares of Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after purchasing an additional 26,856 shares during the last quarter. Retirement Systems of Alabama grew its holdings in shares of Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after purchasing an additional 192,801 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Humana by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock worth $244,811,000 after purchasing an additional 65,735 shares during the period. Finally, PDT Partners LLC increased its position in shares of Humana by 190.0% during the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after purchasing an additional 2,660 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.32% of the company’s stock.

Humana Price Performance

HUM stock opened at $249.32 on Thursday. The company has a market cap of $30.08 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The firm has a 50 day moving average of $271.59 and a 200-day moving average of $281.42.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.42%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Truist Financial boosted their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Twenty analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.